Miller, K. L., Fermaglich, L. J., & Maynard, J. (2021). Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: Substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases. Orphanet J Rare Dis.
Citação norma ChicagoMiller, Kathleen L., Lewis J. Fermaglich, and Janet Maynard. "Using Four Decades of FDA Orphan Drug Designations to Describe Trends in Rare Disease Drug Development: Substantial Growth Seen in Development of Drugs for Rare Oncologic, Neurologic, and Pediatric-onset Diseases." Orphanet J Rare Dis 2021.
Citação norma MLAMiller, Kathleen L., Lewis J. Fermaglich, and Janet Maynard. "Using Four Decades of FDA Orphan Drug Designations to Describe Trends in Rare Disease Drug Development: Substantial Growth Seen in Development of Drugs for Rare Oncologic, Neurologic, and Pediatric-onset Diseases." Orphanet J Rare Dis 2021.